High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis

Saller, Reinhard; Hellenbrecht, D.

doi:10.1016/0277-5379(86)90321-4

Cited by 22 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiemetic agents are designed to target one of these relevant receptors (supplemental online Table 1). Phenothiazine and metoclopramide, agents widely in use from the 1980s, inhibit the action of dopamine . The development of first‐generation serotonergic receptor antagonists (5HT3 inhibitors) in the 1990s effectively suppressed acute CINV particularly when used in tandem with dexamethasone (Dex) , and the combination has been regarded as the standard prophylaxis; however, delayed CINV still remained difficult to control (acute complete response rates 57%–88%, delayed complete response rates 40%–63%).…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Background It is important to control chemotherapy‐induced nausea and vomiting (CINV) to maintain dose intensity and patients' quality of life. The National Comprehensive Cancer Network guidelines suggest combination therapy of antiemetic agents. The growing number of antiemetic regimens, and in particular the growing use of regimens containing antagonists to the Nk‐1 receptor (NK1RAs) and the antipsychotic drug olanzapine (OLZ), call for the re‐evaluation of the optimal regimen for CINV. This study assessed the efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy, using Bayesian network meta‐analysis. Methods Randomized trials that compared different antiemetic regimens were included. We strictly followed Preferred Reporting Items for Systematic Reviews and Meta‐Analysis guidelines. The main outcomes were the odds ratio (OR) for overall complete response (absence of vomiting). We conducted network meta‐analysis within a Bayesian model to combine the direct and indirect evidence. Safety was assessed from the trial description. All statistical tests were two‐sided. Results We systematically reviewed 27 randomized control trials (13,356 participants), which compared 12 different antiemetic regimens: serotonin‐3 receptor antagonist (5HT3), 5HT3 + dexamethasone (Dex), palonosetron (PAL), PAL + Dex, PAL at 0.75 mg (PAL0.75), PAL0.75 + Dex, NK1RA + 5HT3 + Dex, NK1RA + PAL + Dex, an oral combination of netupitant and palonosetron (NEPA) + Dex, OLZ + 5HT3 + Dex, OLZ + PAL + Dex, and OLZ + NK1RA + 5HT3 + Dex. An NK1RA + 5HT3 + Dex regimen and an NK1RA + palonosetron + Dex regimen gave a higher complete response (CR) rate than the reference regimen, 5HT3 + Dex (OR, 1.75; 95% credibility interval [95% CrI], 1.56–1.97, and OR, 2.25; 95% CrI, 1.66–3.03, respectively). A regimen containing NEPA was more effective in producing CR than conventional regimens without NEPA or olanzapine. Further analysis, based on the surface under the cumulative ranking probability curve, indicated that olanzapine‐containing regimens were the most effective in producing CR. Conclusion Our meta‐analysis supports the conclusion that olanzapine‐containing regimens are the most effective for CINV of highly emetogenic chemotherapy. We confirmed that NK1RA + PAL + Dex is the most effective of conventional regimens. Substituting olanzapine for an Nk‐1 receptor antagonist may offer a less costly and more effective alternative for patients. Implications for Practice Nausea and vomiting during chemotherapy often pose difficulties for patients and doctors, making it hard to continue the proper therapy and to maintain the quality of life. This article gives insights into the optimal choice of medicine to treat nausea during chemotherapy. The findings reported here provide readers with a robust efficacy ranking of antinausea medicine, which can be used as a reference for the best possible treatment. Furthermore, the 70% less costly drug, olanzapine, is suggested to be equally effective to aprepitant in reducing nausea and vomi...

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…To our knowledge, in addition to our 5 patients, 38 patients with metoclopramide-induced parkinsonism have been re¬ ported in the literature (Table 3). Typically encountered with¬ in the first 3 months of metoclopramide therapy, the parkinsonian findings resolve in most patients within 2 months after drug therapy is discontinued.16 The recovery period, howev¬ er, may range from 7 days to 1 year.1516 If symptoms persist beyond 18 months, exacerbation of idiopathic Parkinson's disease rather than drug-induced parkinsonism should be considered as the underlying pathogenetic mechanism.60,51 Pa¬ tients with drug-induced parkinsonism tend to be younger and to have bilateral low-amplitude tremor, and the symp¬ toms usually subside within months after discontinuation of treatment with the offending drug.52 This is in contrast to idiopathic Parkinson's disease, which usually affects the el¬ derly, who typically present with an asymmetrical 4to 7-Hz pill-rolling resting tremor.…”

Section: Resultsmentioning

confidence: 82%

Metoclopramide-Induced Movement Disorders

Miller¹

1989

Arch Intern Med

139

View full text Add to dashboard Cite

“…Studies in adult cancer patients have demonstrated that droperidol monotherapy is less effective than treatment with metoclopramide, [94] and may be associated with an increase in extrapyramidal adverse effects. [95] In 2001, the US FDA issued a blackbox warning for droperidol because of case reports of QT interval prolongation and torsades de pointes. However, these cardiac manifestations are thought to occur at doses much higher than those prescribed for the prevention of CINV (0.03-0.07 mg kg dose intramuscularly intravenously every 4-6 hours as needed; maximum 2.5 mg dose), such that the warning should likely not apply to low-dose droperidol.…”

Section: Droperidolmentioning

confidence: 99%

Optimizing Emetic Control in Children Receiving Antineoplastic Therapy

Dupuis

Nathan

2010

Pediatric Drugs

View full text Add to dashboard Cite

Existing guidelines for the prevention of antineoplastic chemotherapy-induced nausea and vomiting (CINV) in children are constrained by the lack of robust evidence. Current guidelines recommend the use of a serotonin 5-HT(3) receptor antagonist plus a corticosteroid to prevent acute CINV. Consequently, antiemetic agents that are recommended for use in adult cancer patients do not appear in the current pediatric guidelines. In addition, there is no information to guide the selection of alternative antiemetic agents for children who either cannot receive the recommended agents or who do not respond adequately to the treatment. Possible barriers to adherence to the pediatric antiemetic selection guidelines that are currently available are discussed, and published pediatric experience with antiemetic agents recommended in the current adult antiemetic selection guidelines (dolasetron, tropisetron, palonosetron, aprepitant) is summarized in this review. The use of novel and emerging antiemetic therapeutic interventions {metopimazine, diphenhydramine (Benadryl)-lorazepam (Avitan)-dexamethasone (Decadron) [BAD], nabilone, acupuncture, midazolam, olanzapine, mirtazapine, gabapentin, droperidol} in children are explored.

show abstract

High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis

Cited by 22 publications

References 12 publications

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis

Metoclopramide-Induced Movement Disorders

Optimizing Emetic Control in Children Receiving Antineoplastic Therapy

Contact Info

Product

Resources

About